TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10194832

Group type: EXPERIMENTAL
Intervention: Rabipur vaccine, administered using the 2-1-1 schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rabipur vaccine
Number of subjects: 0
Study: 7594031

Group type: EXPERIMENTAL
Intervention: Dobutamine stress (infused from 5 micrograms/kg/min up to 40 micrograms/kg/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dobutamine stress
Number of subjects: 12
Study: 1941796

Group type: EXPERIMENTAL
Intervention: 0.4% terconazole cream
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: 0.8% terconazole cream
Number of subjects: 900

Group type: COMPARATOR
Intervention: 2.0% miconazole nitrate cream
Number of subjects: 900
Study: 7199325

Group type: EXPERIMENTAL
Intervention: Midazolam (Ro 21‐3981, Dormicum)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study: 31174535

Group type: EXPERIMENTAL
Intervention: Online yoga (60 min/week)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Wait-list control (maintain normal activity)
Number of subjects: 62
Study: 28834553

Group type: EXPERIMENTAL
Intervention: Exenatide (EXE) 10 μg BID
Number of subjects: 176

Group type: COMPARATOR
Intervention: Metformin (MET) 1000 mg BID
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Exenatide (EXE) during second 12 weeks
Number of subjects: 176

Group type: COMPARATOR
Intervention: Metformin (MET) during second 12 weeks
Number of subjects: 176
Study: 26542510

Group type: EXPERIMENTAL
Intervention: Integration of the GRACE risk score (GRS) into routine ACS patient assessment process
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Integration of the GRS
Number of subjects: 3000
Study: 23343686

Group type: EXPERIMENTAL
Intervention: Intermittent coronary sinus occlusion (iCSO) for 2 minutes
Number of subjects: 35

Group type: COMPARATOR
Intervention: No iCSO (control)
Number of subjects: 35
Study: 22338922

Group type: EXPERIMENTAL
Intervention: Walking exercise with weighted vests (EW, n = 24)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Walking exercise without weighted vests (E, n = 24)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (EW and E)
Number of subjects: 48
Study: 19295387

Group type: EXPERIMENTAL
Intervention: Awake craniotomy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Craniotomy under general anesthesia
Number of subjects: 2

Group type: COMPARATOR
Intervention: Reference group (healthy, age-matched, sex-matched)
Number of subjects: 2
Study: 17562253

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin 40 mg/m(2) and vincristine 1.4 mg/m(2) (maximum, 2 mg) plus reduced‐dose dexamethasone 40 mg orally on days 1‐4 (DVd)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Conventional doxorubicin 9 mg/m(2) per day and vincristine 0.4 mg per day continuous intravenous infusion plus reduced‐dose dexamethasone (VAd)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: DVd
Number of subjects: 192
Study: 14713761

Group type: EXPERIMENTAL
Intervention: Neoadjuvant or adjuvant chemotherapy and radical cystectomy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Basic fibroblast growth factor, interleukin-8, and MMP-9 expression
Number of subjects: 64
Study: 12118900

Group type: EXPERIMENTAL
Intervention: sirolimus 2 mg/day
Number of subjects: 1295

Group type: EXPERIMENTAL
Intervention: sirolimus 5 mg/day
Number of subjects: 1295

Group type: EXPERIMENTAL
Intervention: statins and fibrates
Number of subjects: 1295

Group type: COMPARATOR
Intervention: Framingham risk model
Number of subjects: 1295
Study: 9717677

Group type: EXPERIMENTAL
Intervention: OspA vaccine (30-microgram dose)
Number of subjects: 1634

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 1634
Study: 7867131

Group type: EXPERIMENTAL
Intervention: Vitamin A (52-mumol or 50,000 IU)
Number of subjects: 2067

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2067
Study: 2650588

Group type: EXPERIMENTAL
Intervention: 10 to 20 mg oral nifedipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 336013

Group type: EXPERIMENTAL
Intervention: 25% sodium fluorescein solution
Number of subjects: 83

Group type: COMPARATOR
Intervention: 10% sodium fluorescein solution
Number of subjects: 83
Study: 31759688

Group type: EXPERIMENTAL
Intervention: Wilkins score
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aldrich score
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Selvester score
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ECG-derived myocardial salvage
Number of subjects: 60
Study: 30985571

Group type: EXPERIMENTAL
Intervention: Modic Changes (MCs) group
Number of subjects: 204

Group type: COMPARATOR
Intervention: No Modic Changes (-MC) group
Number of subjects: 204
Study: 28934528

Group type: EXPERIMENTAL
Intervention: High-altitude home polysomnography (H-PSG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lower altitude laboratory polysomnography (L-PSG)
Number of subjects: 10
Study: 26453527

Group type: EXPERIMENTAL
Intervention: 25G needle
Number of subjects: 330
Study: 22820718

Group type: EXPERIMENTAL
Intervention: Approved dose of fospropofol (4.875 or 6.5 mg/kg depending on patient subgroup)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Weight-adjusted dose of fospropofol
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Approved dose of fospropofol
Number of subjects: 153
Study: 21477307

Group type: EXPERIMENTAL
Intervention: NIKE advertisement with the phrase 'LIGHT IT UP' (n = 205)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Neutral advertisement with reduced smoking imagery and the phrase 'GO FOR IT' (n = 192)
Number of subjects: 397
Study: 18955670

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) therapy
Number of subjects: 526

Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 526
Study: 16670647

Group type: EXPERIMENTAL
Intervention: Sleep hygiene intervention
Number of subjects: 27

Group type: COMPARATOR
Intervention: Melatonin (5 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combined sleep hygiene and melatonin
Number of subjects: 27
Study: 12795786

Group type: COMPARATOR
Intervention: GTR alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GTR + Bio‐Oss (DBB‐)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GTR + Bio‐Oss impregnated with gentamicin (DBB+)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flap surgery (RBF)
Number of subjects: 60
Study: 10969261

Group type: EXPERIMENTAL
Intervention: Oat cereal (24 grams per day, 1.2 ± 0.9 g/kg/d)
Number of subjects: 10
Study: 8771109

Group type: EXPERIMENTAL
Intervention: Autovac system with calcium binding resin anticoagulant
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Autovac system with acid citrate dextrose anti-coagulate (ACD‐A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard drain (control group)
Number of subjects: 50
Study: 1448821

Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg twice daily
Number of subjects: 927

Group type: COMPARATOR
Intervention: Aspirin 650 mg twice daily
Number of subjects: 927
Study: 3989764

Group type: EXPERIMENTAL
Intervention: Stapling
Number of subjects: 74

Group type: COMPARATOR
Intervention: Suturing
Number of subjects: 74
Study: 28916304

Group type: EXPERIMENTAL
Intervention: Infusion of dilute mesenchymal stem cells (MSCs)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Infusion of concentrated mesenchymal stem cells (MSCs)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 26541647

Group type: EXPERIMENTAL
Intervention: Book reading
Number of subjects: 69

Group type: COMPARATOR
Intervention: Toy play
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Variation in speech characteristics
Number of subjects: 69
Study: 25402840

Group type: EXPERIMENTAL
Intervention: Conventional optical microscopy
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Phase‐contrast microscopy
Number of subjects: 131
Study: 23134837

Group type: EXPERIMENTAL
Intervention: Silver alloy-coated catheter
Number of subjects: 7102

Group type: EXPERIMENTAL
Intervention: Nitrofural-impregnated catheter
Number of subjects: 7102

Group type: COMPARATOR
Intervention: PTFE-coated catheter (control group)
Number of subjects: 7102
Study: 19716540

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study: 18550961

Group type: COMPARATOR
Intervention: C (Caffeine 300 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: C + E (Caffeine 300 mg + Ephedra 60 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: P (Placebo 300 mg)
Number of subjects: 9
Study: 16210886

Group type: EXPERIMENTAL
Intervention: Once-daily administration of fluticasone propionate (200 microg at night)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Twice-daily administration of fluticasone propionate (100 microg in the morning and at night)
Number of subjects: 40
Study: 15769705

Group type: EXPERIMENTAL
Intervention: Ethicon steel band in addition to standard osteosynthesis with 8 wire cerclages
Number of subjects: 0
Study: 10896070

Group type: COMPARATOR
Intervention: Fiber-only comparison group
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fiber and biofeedback-assisted cultivated low arousal
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fiber, biofeedback, and cognitive-behavioral interventions
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fiber, biofeedback, cognitive-behavioral, and parental support
Number of subjects: 64
Study: 9017662

Group type: EXPERIMENTAL
Intervention: [3H]8‐OH‐DPAT binding in the hippocampus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: [3H]8‐OH‐DPAT binding in the striatum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: [3H]8‐OH‐DPAT binding in the frontal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GTP gamma S modulation in hippocampus and frontal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divalent cation effects in striatum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divalent cation effects in hippocampus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divalent cation effects in frontal cortex
Number of subjects: 0
Study: 8336527

Group type: EXPERIMENTAL
Intervention: Low sodium diet (40 mmol of sodium daily)
Number of subjects: 115

Group type: COMPARATOR
Intervention: High sodium diet (120 mmol of sodium daily)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: K-canrenoate (200 mg/day increasing to 600 mg)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Furosemide (25-50-100 mg every other day)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Washout period of 7 days from outpatient diuretic regimen
Number of subjects: 115
Study: 3535972

Group type: EXPERIMENTAL
Intervention: Viloxazine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 29985433

Group type: EXPERIMENTAL
Intervention: Selective Triple Antithrombotic Therapy (TATT)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Ticagrelor-based Dual Antiplatelet Therapy (DAPT)
Number of subjects: 177
Study: 26653111

Group type: EXPERIMENTAL
Intervention: GH 1 mg/m(2)/d
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: GH 2 mg/m(2)/d
Number of subjects: 110

Group type: COMPARATOR
Intervention: Combined GH/GnRHa
Number of subjects: 110

Group type: COMPARATOR
Intervention: GH only
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: GH 1 mg/m(2)/d with GnRHa
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: GH 2 mg/m(2)/d with GnRHa
Number of subjects: 110
Study: 24727639

Group type: EXPERIMENTAL
Intervention: Measures based on the Automobile NOx/PM law
Number of subjects: 618973

Group type: EXPERIMENTAL
Intervention: Reduction in ambient air pollution (NO2 and SPM)
Number of subjects: 618973

Group type: EXPERIMENTAL
Intervention: Increase in ambient air pollution (NO2 and SPM)
Number of subjects: 618973

Group type: COMPARATOR
Intervention: Non-enforced areas (control)
Number of subjects: 618973

Group type: EXPERIMENTAL
Intervention: Changes in air pollutant concentrations
Number of subjects: 618973
Study: 22781921

Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression (PFD) surgery
Number of subjects: 167
Study: 20852415

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical embolectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catheter-based embolectomy
Number of subjects: 0
Study: 18514906

Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/d
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 70
Study: 16162203

Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Everolimus 3 mg/day
Number of subjects: 588

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 2 g/day
Number of subjects: 588
Study: 12669270

Group type: EXPERIMENTAL
Intervention: ACE gene I/D polymorphism (DD, ID, II genotypes) in patients with CHD
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: ACE gene I/D polymorphism in patients with diabetes mellitus
Number of subjects: 691
Study: 11061069

Group type: EXPERIMENTAL
Intervention: Urinary incontinence (UI) prevalence
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Risk factors for UI
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Types of UI by gender
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Intention to seek treatment for UI
Number of subjects: 504
Study: 8889418

Group type: EXPERIMENTAL
Intervention: Aprotinin 0.2 mg kg‐1 (group A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aprotinin 0.7 mg kg‐1 (group B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aprotinin 1 mg kg‐1 (group C)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aprotinin 1.4 mg kg‐1 (group D)
Number of subjects: 48
Study: 1739325

Group type: EXPERIMENTAL
Intervention: Rectal temperature measurement
Number of subjects: 937

Group type: COMPARATOR
Intervention: Axillary temperature measurement
Number of subjects: 937
Study: 6200173

Group type: EXPERIMENTAL
Intervention: methyl CCNU and 5‐Fluorouracil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 0
Study: 31340849

Group type: EXPERIMENTAL
Intervention: Repetitive vascular occlusion stimulus (RVOS) applied twice daily (once on day 1) for up to 10 days or until ICU discharge
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 32
Study: 29486489

Group type: EXPERIMENTAL
Intervention: On-demand nebulization of acetylcysteine or salbutamol (n=471)
Number of subjects: 922

Group type: COMPARATOR
Intervention: Routine nebulization of acetylcysteine with salbutamol (every 6 hours until end of invasive ventilation, n=473)
Number of subjects: 922

Group type: COMPARATOR
Intervention: Routine nebulization (n=473)
Number of subjects: 922
Study: 23181708

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: petrolatum (placebo)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Presence of autoantibodies
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Absence of autoantibodies
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atopy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nail involvement
Number of subjects: 60
Study: 22807477

Group type: EXPERIMENTAL
Intervention: Individualised dose of oral 17β-oestradiol (5-15 μg/kg per day for 2 years)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fixed dose of oral 17β-oestradiol (0.2 mg daily for the first year, 0.5 mg daily for the second year)
Number of subjects: 48
Study: 21225018

Group type: COMPARATOR
Intervention: Fluticasone nasal spray (200 μg in each nostril) once a day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fluticasone nasal spray (200 μg in each nostril) plus cetrizine (10 mg) orally once a day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray (200 μg in each nostril) plus montelukast (10 mg) orally once a day
Number of subjects: 90
Study: 17681971

Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with ropivacaine 0.487% plus clonidine 5 microg ml(‐1) (Group RC)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with ropivacaine 0.487% (Group R)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Bilateral superficial cervical plexus block with saline (Group P)
Number of subjects: 87
Study: 15754237

Group type: EXPERIMENTAL
Intervention: Lumbar paravertebral nerve root infiltration
Number of subjects: 117

Group type: COMPARATOR
Intervention: First treatment with lumbar paravertebral nerve root infiltration
Number of subjects: 117
Study: 11999889

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 119
Study: 9949220

Group type: EXPERIMENTAL
Intervention: Cocaine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cocaine and Control
Number of subjects: 26
Study: 7561228

Group type: EXPERIMENTAL
Intervention: Eutectic Mixture of Local Anesthetics (EMLA) (N = 49)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (N = 47)
Number of subjects: 96
Study: 2358004

Group type: EXPERIMENTAL
Intervention: Flunarizine (12 patients)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (14 patients)
Number of subjects: 26
Study: 526399

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bethanidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment (Labetalol + Bethanidine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study: 30606273

Group type: EXPERIMENTAL
Intervention: IPS-WFM combination
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (equally intensive clinical treatment)
Number of subjects: 69
Study: 30448355

Group type: EXPERIMENTAL
Intervention: LUS-guided treatment strategy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care treatment strategy
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: LUS-guided care
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study: 28658126

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target SBP 120-140 mm Hg) for 7 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target SBP 140-180 mm Hg) for 7 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 80
Study: 25802841

Group type: EXPERIMENTAL
Intervention: MFT‐8
Number of subjects: 16

Group type: COMPARATOR
Intervention: MFT
Number of subjects: 16
Study: 22946979

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stabilization splint
Number of subjects: 20
Study: 21653660

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 54
Study: 19267733

Group type: EXPERIMENTAL
Intervention: Benzydamine oral rinse
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 17904460

Group type: EXPERIMENTAL
Intervention: Multi-modal quality improvement intervention (audit and feedback, educational modules, teleconferences, academic detailing)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Completion of educational module
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Direct physician contact by an academic detailer
Number of subjects: 606
Study: 15379416

Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Children with hyperlipidemia
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-obese controls
Number of subjects: 48
Study: 16924985

Group type: EXPERIMENTAL
Intervention: Etch and rinse adhesive systems (SBMP, OS, SB1, G)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Self-etch adhesive systems (PLP, X-III, iB)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: X-III (self-etch adhesive)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Flowable composite lining under PLP adhesive
Number of subjects: 70
Study: 10908001

Group type: EXPERIMENTAL
Intervention: manualized, cognitive‐behavioral outpatient treatment developed by the Matrix Center in Los Angeles
Number of subjects: 0

Group type: COMPARATOR
Intervention: treatment approaches currently employed by the treatment sites
Number of subjects: 0
Study: 8700338

Group type: EXPERIMENTAL
Intervention: Mepartricin 150,000 U (40 mg) once in the evening for 60 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Mepartricin 50,000 U (13 mg) t.d.s.
Number of subjects: 25
Study: 1656828

Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 41

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study: 7058868

Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline treatments
Number of subjects: 0
Study: 31657011

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Systemic Therapy (ST)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison of ST vs CBT
Number of subjects: 38
Study: 30791796

Group type: EXPERIMENTAL
Intervention: Critical Time Intervention-Task Shifting (CTI-TS)
Number of subjects: 15
Study: 29792215

Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAACS)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 187
Study: 27184790

Group type: EXPERIMENTAL
Intervention: Early intervention programs aimed at developing parents’ relationship and parenting skills.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Maternal sensitivity and mother’s psychosocial stress.
Number of subjects: 53
Study: 24957530

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18624

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18624
Study: 22295817

Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture (treatment at Zhongwan (CV 12), Shangqu (KI 17) on healthy side, Huaroumen (ST 24) on affected side)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Acupuncture (treatment at Jianyu (LI 15), Jianliao (TE 14), Jianzhen (SI 9) on affected side)
Number of subjects: 96